NHS funding boost for cancer diagnosis
March 8, 2010Cancer, NHS, disease awareness campaigns
The government is to put £8 million into finding new ways of improving early cancer diagnosis for one or more …
Vidaza too costly for NICE
March 8, 2010Sales and Marketing Celgene, NICE, Vidaza
NICE has rejected Celgene’s Vidaza for use on the NHS to treat the rare bone marrow disease myelodysplastic syndrome. The …
Roche halts ocrelizumab trials
March 8, 2010Research and Development RoActemra, ocrelizumab, rheumatoid arthritis
The future of Roche and Biogen Idec’s rheumatoid arthritis drug ocrelizumab has been thrown into doubt after the manufacturers decided …
Wiley-Blackwell appoints Dr Charles Young
March 8, 2010Medical Communications Wiley, Wiley-Blackwell, appointment, medical communications
Dr Charles Young has joined Wiley-Blackwell as publishing director of global clinical solutions. He moves to the company from the …
Ethex closed down after US court levies $27.6m in fines
March 8, 2010Manufacturing and Production Ethex, KV Pharma, manufacturing and production
Generic drugmaker Ethex Corp has been fined $27.6 million by a US District Court after pleading guilty to two felony …
Orphan and rare disease marketers: are you armed for success?
March 8, 2010Business Services, Sales and Marketing Orphan
Many marketers are currently unfamiliar with the specific approaches required in orphan and rare disease (ORD) brands, but will need …
Adventis Health restructures
March 8, 2010Medical Communications Adventis, medical communications
Adventis Health has restructured its client service teams in a move the coms agency says will allow it to better …
Digital Pharma: Byte-sized roundup
March 8, 2010Medical Communications Pfizer, digital pharma, digital pharma pfizer
A roundup of digital developments, including Pfizer’s new Facebook page and beta-phase science blog, Lundbeck, BMS, Baxter and Janssen-Cilag on …
Stricter monitoring for UK supply chain
March 5, 2010parallel trade, supply chain
New measures to ensure that the UK doesn’t suffer from shortages of prescription medicines have been announced by the government. …
Phase III success for apixaban
March 5, 2010Research and Development BMS, Pfizer, VTE, apixaban
Pfizer and Bristol-Myers Squibb’s apixaban has shown promising results in a late-stage head-to-head trial with Sanofi-Aventis’ Lovenox. The oral anti-coagulant …
Roche cancer drug gets NICE thumbs up
March 5, 2010Sales and Marketing MabThera, Roche
NICE has recommended Roche’s MabThera to treat patients with the most common form of leukaemia, relapsed or refractory chronic lymphocytic …
FDA encourages cell-based vaccine production
March 5, 2010Manufacturing and Production h1n1, swine flu
The US Food and Drug Administration has issued a new guidance document designed to help encourage the adoption of cell-based …
Sudler & Hennessey London expands
March 5, 2010Medical Communications Sudler & Hennessey, appointments, medical communications
Sudler & Hennessey London has added ten new members to its team, expanding its account handling and creative departments. Group …
NICE asks Roche for RoActemra cost data
March 5, 2010Sales and Marketing RoActemra, Roche
Roche’s attempts to secure NICE approval for rheumatoid arthritis drug RoActemra have hit another hurdle. NICE’s independent appraisal committee has …
Merck appoints Bridgette Heller
March 5, 2010Sales and Marketing Merck, appointment, consumer healthcare, sales and marketing
Bridgette Heller has joined Merck & Co as executive vice president and president, consumer health care. She moves to Merck …
Just teams up with sexual health charity
March 5, 2010Medical Communications FPA, charity, contraception, just health pr
Just Health PR is providing PR support for the launch of a new UK consumer book on contraception from sexual …
Kantar Health promotes Ceri Thomas
March 4, 2010Sales and Marketing Kantar Health, appointment, sales and marketing
Ceri Thomas has been promoted to head of global marketing at healthcare consultancy and marketing insights company Kantar Health. In …
Pfizer suffers Alzheimer’s setback
March 4, 2010Research and Development Alzheimer's, Medivation, Pfizer
Pfizer has suffered a big setback with the oral Alzheimer’s disease treatment it is developing with biotech outfit Medivation. Investigational …
HCA: Five years of change in healthcare communications
March 4, 2010Medical Communications HCA, industry reputation
In 2005 the Healthcare Communications Association (HCA) conducted its first ever benchmarking survey, exploring trends in the provision of communications …
Lamberto Andreotti new head of Bristol-Myers Squibb
March 4, 2010Research and Development, Sales and Marketing BMS, appointment, research and development, sales and marketing
Bristol-Myers Squibb has appointed Lamberto Andreotti its new chief executive with effect from 4 May, succeeding James Cornelius who will …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
